tbuckley/cabot-search huggingface dataset:
Shock Wave Therapy for Treatment of Plantar Fasciitis—Reply
Authors: Rachelle Buchbinder, Andrew Forbes, Ronnie Ptasznik
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A retrospective study of immunohistochemical detection of Ki67 and correlation with ER, PR, and HER2-neu status in invasive breast cancer.
Authors: Deepa Meda Prakash, Swarna Shivakumar, P P Bapsy
Journal: Journal of Clinical Oncology (2012)

e21132 Background: Carcinoma breast is a heterogeneous group of disease. Several prognostic factors are known to predict the biological behavior and clinical outcome of breast cancer, including proliferation index, tumor size, age, histological grade, hormone receptors and Her2Neu status. Of theses proliferative index is the most important parameter in predicting tumor aggressiveness and prognosis. Ki67 is a nuclear protein, tightly linked to the cell cycle and is a marker of cell proliferation. High Ki67 usually correlates with a poor prognosis in breast cancer. Methods: This exploratory study is initiated whether Ki67 will be an additional prognostic factor. Immunohistochemical staining of Ki 67 was performed on formalin fixed paraffin embedded blocks of 50 cases of histologically confirmed breast cancer. Ki 67 expression based on distinct nuclear staining of tumor cells was assessed semiquantitatively as, nil (no immunostaining), low (≤10% immunopositivity), high (&gt;10% immunopositivity) by light microscope. ER, PR, Her 2neu status and clinico-pathological parameters were analyzed and correlated with Ki67 immunostaining using the x 2 test. Results: Our study showed high Ki 67 staining in 24 cases(48%), low immunostaining in 18 cases(36%) and was nil in 5 cases (10%) and was inconclusive in 3 cases(6%) (core biopsies). There was an inverse correlation of Ki 67 with ER, PR scores in 32 cases (64%) and positive correlation was seen in 28 cases (56%) with Her2 neu status. A good correlation was also observed with mitotic index in 37cases (74%) and histological grade in 29 cases (58%). Good correlation was seen with large tumor size in 24 cases(48%) and metastatic disease 9 cases (64%). Poor correlation was observed with node positive 22 cases (44%). High Ki 67 expression with good treatment response was seen in 13 cases (26%). Conclusions: Based on our study, Ki 67 score may prove to be an important prognostic factor in breast cancer and thereby, useful in making therapeutic decisions. But this is being explored in a large prospective study.
IMPACT OF INTRA-OPERATIVE TRANSFUSIONS ON POST LEFT VENTRICULAR ASSIST DEVICE PLACEMENT OUTCOMES: A SINGLE CENTER STUDY
Authors: Hector Sepulveda Alemany, Ozan Unlu, Maria Pabon, Irina Sobol, Udhay Krishnan, Parag Goyal, Evelyn Horn, Nicholas Williams, Farhan Raza, Maria Karas
Journal: Journal of the American College of Cardiology (2020)
Biweekly schedule of cisplatin with prolonged infusion of gemcitabine in advanced non small cell lung cancer (NSCLC)
Authors: G. López-Vivanco, I. Rubio, J. Mañé, A. Viteri, N. Ancizar, A. Muñoz, R. Barceló, N. Fuente, A. Ruiz de Lobera, G. López-Argumedo
Journal: Journal of Clinical Oncology (2006)

17093 Background: Firstly, we conducted a phase I of a biweekly schedule of cisplatin with prolonged infusion of gemcitabine (10 mg/m 2 /min) and stablished the dose to perform a phase II. We present final results of a phase II with this combination. Methods: Patients with cytologically or histologically confirmed NSCLC stage IIIB and IV were included. Treatment consisted of Cisplatin 50 mg/m 2 days 1 and 15 with Gemcitabine 1600 mg/m 2 in 160 minutes (10 mg/m 2 /min), days 1 and 15 every 28 days. Chemotherapy was administered to a maximum of 6 cycles; if radiotherapy was planned, patients received 4 cycles. Results: From March-04 to January-05, 55 patients were included. Patient characteristics: Median age 59 years (35–75). Gender: 51 male 4 female. ECOG performance status 0/1/2: 8/43/4. Histology: Squamous cell carcinoma 26 (47.3%), adenocarcinoma 22 (40%), large cell carcinoma 2 (3.6%), undifferentiated 5 (9%). Stage: IIIA 2 (3.6%), IIIB 27 (49.1%) and IV 26 (47.3%). Treatment compliance: Administrations: Mean 6.7 and median 8 (1–12). Dose intensity: Cisplatin 20.35 mg/m 2 /week (81%) Gemcitabine 632.61 mg/m 2 /week (79%). Toxicity: Extrahematological toxicity grade 3/4 per patient: nausea 10/0, emesis 6/0, asthenia 31/1, anorexia 14/0, mucositis 1/0, diarrhoea 1/1, infection 4/0, hepatic 2/0, vascular 0/1 (pulmonary thromboembolism). Neurotoxicity grade 1, 13 pt and grade 2, 1 pt. Hematological toxicity grade 3/4: anemia 1/0, thrombocytopenia 5/1, neutropenia 21/9 and neutropenic fever 4/0. Nine patients were hospitalised due to toxicity. There was one toxic death. Response rate: Response was evaluated in 52 pt (3 pt died after first cycle). Overall response rate was 38.1% (95% CI 50.93–25.26%). Complete response 2 (3.6%), Partial response 19 (34.5%), Stable disease 23 (41.8%), Progressive disease 8 (14.5%). Survival: Overall median survival was 9.6 months (95% CI 7.76–11.43): stage III 10.46 and stage IV 8.8. Overall progression-free survival was 8.06 months (95% CI 5.95–10.18): stage III 8.9 and stage IV 6.3. Conclusions: Biweekly cisplatin with prolonged infusion of gemcitabine is an active regimen for advanced NSCLC with a good toxicity profile. This better rational way of gemcitabine infusion should be more profoundly explored. No significant financial relationships to disclose.
Predictive value of serum nitric oxide for bevacizumab response in patients with non-small cell lung cancer.
Authors: Hiroyuki Suzuki, Jun Ohsugi, Takeo Hasegawa, Hiroshi Yaginuma, Naoyuki Okabe, Satoshi Muto, Yuki Owada, Mitsukazu Gotoh
Journal: Journal of Clinical Oncology (2013)

e19162 Background: Bevacizumab (BEV), an inhibitory monoclonal antibody to VEGF, is widely used to treat patients with non-small cell lung cancer (NSCLC), but biomarkers that predict BEV response are controversial. Reportedly, hypertension is linked to response to BEV therapy, possibly because BEV might suppress vascular nitric oxide (NO) production. However, the usefulness of serum NO (NO s ) as a predictive biomarker for BEV therapy has not previously been shown. Here, we studied the predictive value of NO s in BEV-treated patients with NSCLC. Methods: Fifteen patients with advanced or recurrent NSCLC treated with BEV-based regimens were evaluated retrospectively. Blood samples were taken before treatment (Pre), and after the 1st and 2nd chemotherapy courses (Post 1 and Post 2 , respectively). NO s (NO 2 – /NO 3 – ) was assayed by the Griess method. Relationships between clinical parameters (e.g., clinical responses, adverse events) were analyzed against NO s . This study was approved by the ethics committee of Fukushima Medical University. Results: Mean Pre NO s was 70.3 ±10.5 μmol/L (range: 7.7–138.6 μmol/L). Significant decreases were observed at Post 1 (34.6 ± 6.4 μmol/L; P = 0.013) and Post 2 (29.6 ± 7.6 μmol/L; P = 0.046) compared to Pre values. Post/Pre NO ratios correlated significantly with hypertension onset (Post 1 /Pre: P = 0.012; Post 2 /Pre: P = 0.001). Notably, Post/Pre NO ratios correlated with clinical treatment responses—significantly so for Post 2 /Pre (Post 1 /Pre: P = 0.06; Post 2 /Pre: P = 0.005). Conclusions: NO s , could be a predictive biomarker for response to BEV in patients with NSCLC. Prospective confirmation is needed; we are conducting a prospective translational study of NO in BEV therapy. [Table: see text]
DIFFERENTIAL DIAGNOSTIC ACCURACY OF RESTING NON-HYPEREMIC PRESSURE RATIOS (NHPR) IN RCA VERSUS LEFT CORONARY LESIONS
Authors: Linle Hou, Kulin Shah, Bobby Ghosh, Shiv Kumar Agarwal, Srikanth Kasula, Barry F. Uretsky, Abdul Hakeem
Journal: Journal of the American College of Cardiology (2020)
Clinical considerations in individuals with α<sub>1</sub>-antitrypsin PI*SZ genotype
Authors: Gerard N. McElvaney, Robert A. Sandhaus, Marc Miravitlles, Gerard M. Turino, Niels Seersholm, Marion Wencker, Robert A. Stockley
Journal: European Respiratory Journal (2020)

α 1 -Antitrypsin deficiency (AATD), characterised by reduced levels or functionality of α 1 -antitrypsin (AAT), is a significantly underdiagnosed genetic condition that predisposes individuals to lung and liver disease. Most of the available data on AATD are based on the most common, severe deficiency genotype (PI*ZZ); therefore, treatment and monitoring requirements for individuals with the PI*SZ genotype, which is associated with a less severe AATD, are not as clear. Recent genetic data suggest the PI*SZ genotype may be significantly more prevalent than currently thought, due in part to less frequent identification in the clinic and less frequent reporting in registries. Intravenous AAT therapy, the only specific treatment for patients with AATD, has been shown to slow disease progression in PI*ZZ individuals; however, there is no specific evidence for AAT therapy in PI*SZ individuals, and it remains unclear whether AAT therapy should be considered in these patients. This narrative review evaluates the available data on the PI*SZ genotype, including genetic prevalence, the age of diagnosis and development of respiratory symptoms compared with PI*ZZ individuals, and the impact of factors such as index versus non-index identification and smoking history. In addition, the relevance of the putative 11 µM “protective threshold” for AAT therapy and the risk of liver disease in PI*SZ individuals is explored. The purpose of this review is to identify open research questions in this area, with the aim of optimising the future identification and management of PI*SZ individuals.
Feasibility study of SNPs detection associated with breast cancer by genome-wide association virtual studies.
Authors: Mohammad Mehdi Kooshyar, Mohammadreza Nassiri, Aliasghar Aslaminezad, Morteza Betaraf
Journal: Journal of Clinical Oncology (2013)

e22167 Background: Available genomic data and genome-wide association virtual studies (GWAS), provide possibility of genetic markers detection known to be associated with the complex diseases. Genome-wide association studies, involving direct testing of genetic polymorphisms in large series of disease cases versus controls, provide a powerful approach to identify lower penetrance alleles that cannot be detected by genetic linkage studies. Methods: By utilizing genotyping platforms that can type hundreds of thousands of SNPs simultaneously, it is possible to conduct association studies using sets of SNPs that tag most known common variants in the genome, and hence scan associations without prior knowledge of function or position. GWAS have been conducted in five of the most common cancer types: breast, prostate, colorectal, lung and melanoma. GWAS of breast cancer was performed by simulation of 7 known SNPs on chromosomes 2, 5, 6, 8, 10, 11 and 16 for 10,000 women. Results: The strongest associations were found for rs2981582 in the FGFR2 gene. SNPs: rs889312 ° rs2180341 and rs3817198 were associated with breast cancer in benferroni significant level. However, SNPs: rs 13387042 ° rs2180341 and rs13281615 on chromosomes 2, 6 and 8 were not associated with breast. Conclusions: Results of this research show that the detection of SNPs associated with disease is easily possible through employing virtual systems based on real data of Hap Map project by using R software.
Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction.
Authors: Lisanne Krens, Jara Baas, Floris A. de Jong, Henk-jan Guchelaar, Hans Gelderblom
Journal: Journal of Clinical Oncology (2013)

594 Background: Panitumumab is used for the treatment of metastatic KRAS wild type (WT) colorectal cancer (mCRC). It is likely that many of these patients will present with liver metastases and some with liver dysfunction. The pharmacokinetics in patients with hepatic impairment are unknown and dosage adjustments are undetermined. Here, we present a case of a patient with progressive mCRC and liver dysfunction. Methods: A heavily pre-treated KRAS WT mCRC patient with liver disease Child-Pugh class B was treated with two-weekly 6 mg/kg panitumumab. The patient received 2 doses of 490 mg iv panitumumab after which progressive disease was documented. Toxicities were graded using CTCAEv4.0. Serum samples were collected and panitumumab concentrations were determined using a validated immunoassay. PK parameters after the first dose, including dose-normalized AUC from time zero–day 14, clearance (CL), and elimination half-life (T 1/2 ), were estimated via trapezoidal non compartmental methods. Data was compared to historical data from a normal population as reported by Stephenson (Clin Colorectal Cancer 2009). Values within the range of the mean ± 1 standard deviation (SD) were considered not deviant. Results: Calculated AUC after the first dose of 6 mg/kg panitumumab in this patient with hepatic dysfunction was 877 μg*day/mL (Stephenson’s cohort 1: 744 ± 195 μg*day/mL). Estimated T 1/2 was 3.58 days (5.28 ± 1.90 days) and CL was 6.9 mL/day/kg (8.21 ± 3.79 mL/day/kg). Estimated PK parameters during the first cycle were inside reported mean ± 1 SD of historical controls without liver dysfunction. No toxicity was reported during treatment, particularly, no diarrhea and skin toxicity. Conclusions: The pharmacokinetics of panitumumab in this patient suffering from colorectal cancer with liver dysfunction Child-Pugh class B was similar when compared to patients with adequate liver functions. Moreover, no substantial toxicity was detected. The here presented data may help clinical decision making in real life practice. Two-weekly panitumumab monotherapy seems to be safely applicable in patients with KRAS WT mCRC and hepatic dysfunction without the need for dose adjustments.
Melanoma of ocular, mucosal, and genital sites: Epidemiology and survival outcomes.
Authors: Kenneth D. Bishop, Adam J. Olszewski
Journal: Journal of Clinical Oncology (2013)

9051 Background: Melanomas arising from noncutaneous sites are rare entities with poorly defined staging, prognosis and no evidence-based treatment guidelines. Methods: We analyzed melanoma cases in the Surveillance, Epidemiology and End Results database between 1988 and 2007. Differences in clinical and pathologic features, treatment, and mortality were studied according to primary site of disease. The risk of melanoma-related death was calculated from life tables based on expected survival. Relative survival was compared in a multivariable parametric model using individual data. Results: We identified 209,861 cases of melanoma, of which 9,267 (4.4%) were noncutaneous. These were notable for older age, higher proportion of women, racial minorities, and advanced-stage disease. Mortality was high, even in subgroups with localized stage at diagnosis. Mucosal melanomas of the gastrointestinal and genitourinary tract had the highest excess mortality hazard ratios (HR) in the multivariate model. A substantial proportion of patients underwent organ-specific radical resection (32% eye enucleation, 40% radical head/neck surgery, 31% gastrectomy, 23% abdominoperineal resection). Conclusions: Melanoma arising from mucosal sites portends markedly worse prognosis than cutaneous melanoma. Prospective studies of systemic adjuvant treatment are needed for this disease, which is rarely curable even with aggressive local therapy. [Table: see text]
DIAGNOSIS OF NATIVE VALVE, PROSTHETIC VALVE AND IMPLANTABLE CARDIAC DEVICE LEAD INFECTIVE ENDOCARDITIS USING 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY: A CONTEMPORARY META-ANALYSIS
Authors: Tom Kai Ming Wang, Alejandro Sanchez, Efehi Igbinomwanhia, Paul Cremer, Brian P. Griffin, Bo Xu
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION BETWEEN DONOR TRANSMITTED ATHEROSCLEROSIS AND CARDIOVASCULAR OUTCOMES AFTER HEART TRANSPLANT
Authors: Raed Qarajeh, Mohamed Omer, Hunter Brandt, David Safley, A. Michael Borkon, Mark Everley, Timothy Fendler, Andrew Kao, Taiyeb Khumri, Stephanie Lawhorn, Anthony Magalski, Michael Nassif, Deepthi Vodnala, Bethany Austin, Brett Sperry
Journal: Journal of the American College of Cardiology (2020)
<scp>COVID</scp>‐19 and mycoplasma pneumoniae coinfection
Authors: Bingwen Eugene Fan, Kian Guan Eric Lim, Vanessa Cui Lian Chong, Stephrene Seok Wei Chan, Kiat Hoe Ong, Ponnudurai Kuperan
Journal: American Journal of Hematology (2020)

A 36-year-old Chinese man with a recent diagnosis of COVID-19 infection was treated in the National Centre for Infectious Diseases, Singapore. He was found to have severe lymphopenia and moderate thrombocytopenia on admission to ICU and required ventilatory support. Peripheral blood smear performed in view of a rising MCV from 86 fL to 92 fL demonstrated cold agglutination and rouleaux formation, lymphopenia with few reactive lymphocytes and rare lymphoplasmacytoid cells (Image 1A,B, Wright stain, 100x objective). There was no significant anemia or biochemical haemolysis and direct agglutination test was negative. Antibody screen revealed anti-I antibody, a cold agglutinin titer of 1:8 with a mycoplasma pneumoniae antibody titer of 1:160. Serum electrophoresis did not show a monoclonal antibody. Respiratory multiplex PCR for other common respiratory viruses was negative. Reactive lymphocytes are frequently seen in COVID-19 infection (unlike in SARS), while in mycoplasma pneumoniae infection cold agglutination is common. COVID-19 coinfection with other common respiratory pathogens such as mycoplasma pneumoniae may exacerbate clinical symptoms, increase morbidity and may cause prolonged ICU stay if left undetected or untreated. Clinicians managing patients with COVID-19 infection should be mindful of coinfections with common respiratory pathogens during this COVID-19 outbreak and screen for these with appropriate microbiologic tests.
ELECTROCARDIOGRAM, CLINICAL, AND ECHOCARDIOGRAM-BASED PREDICTION OF FAT AND FIBROTIC INVASION IN THE LEFT VENTRICULAR MYOCARDIUM ON FOUR-DIMENSIONAL (4D) CARDIAC COMPUTED TOMOGRAPHY IN PATIENTS WITH ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
Authors: Nobusada Funabashi, Masahiro Okamoto, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2020)
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Authors: Kei Kunimasa, Risa Kamada, Toru Oka, Makiko Oboshi, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Tatsuya Nishikawa, Taku Yasui, Wataru Shioyama, Kazumi Nishino, Fumio Imamura, Toru Kumagai, Masashi Fujita
Journal: JACC CardioOncology (2020)

The purpose of this study was to assess osimertinib-associated cardiac adverse events (AEs) in a real-world setting, using a retrospective single-center cohort study in Japan. Cases of osimertinib-associated cardiac AEs have been reported but remain poorly understood. A total of 123 cases of advanced non–small cell lung cancer (NSCLC) with confirmed EGFR mutations who received osimertinib monotherapy from 2014 to 2019 at the Osaka International Cancer Institute (Osaka, Japan) were evaluated. Cardiac AEs were defined according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Changes in left ventricular ejection fraction (LVEF) and rates of cancer therapeutics-related cardiac dysfunction (CTRCD), defined as a ≥10 % absolute decline in LVEF from baseline to a value of <53%, were further assessed in 36 patients in whom serial measurements of LVEF were obtained before and during osimertinib treatment. Severe cardiac AEs (CTCAE grade 3 or higher) occurred in 6 patients (4.9%) after osimertinib administration. These AEs included acute myocardial infarction (n = 1), heart failure with reduced LVEF (n = 3), and valvular heart disease (n = 2). Five of the 6 patients had a history of cardiovascular risk factors or disease. Myocardial biopsies in 2 of the patients showed cardiomyocyte hypertrophy and lipofuscin deposition. In 36 patients assessed with serial LVEF, LVEF declined from 69.4 ± 4.2% to 63.4 ± 10.5% with osimertinib therapy (p < 0.001). CTRCD occurred in 4 patients with a nadir LVEF of 40.3 ± 9.1% with osimertinib. In this retrospective cohort analysis, the incidence of cardiac AEs in patients treated with osimertinib was 4.9%. Additional prospective data collected from patients with NSCLC treated with osimertinib will be important in understanding the incidence, pathophysiology, and management of cardiac AEs with osimertinib.
Abstract 14758: Explore the Mechanisms for the Development of Post-Splenectomy Cardiovascular Complications in a Thalassemic Murine Model
Authors: Ling Wang, Jonas Sertorio, Charles F McTiernan, Timothy Bachman, Jeff Baust, Zeyu Xiong, Janet S Lee, Mark T Gladwin
Journal: Circulation (2018)

Introduction: Growing clinical evidence suggest splenectomy in hemolytic disorders is independently associated with higher risk of cardiovascular complications, including pulmonary hypertension (PH...
NOVEL ORAL ANTICOAGULANTS ARE SAFE AND EFFECTIVE FOR THROMBOEMBOLIC PROPHYLAXIS IN OBESE PATIENTS WITH ATRIAL FIBRILLATION
Authors: Christopher Bianco, Sijin Wen, Yilin Cai, Christopher Finch, Wesley Kimble, Marco Caccamo, George G. Sokos
Journal: Journal of the American College of Cardiology (2020)
Nicotinamide nucleotide transhydrogenase regulates mitochondrial metabolism in NSCLC through maintenance of Fe-S protein function
Authors: Nathan P. Ward, Yun Pyo Kang, Aimee Falzone, Theresa A. Boyle, Gina M. DeNicola
Journal: The Journal of Experimental Medicine (2020)

Human lung tumors exhibit robust and complex mitochondrial metabolism, likely precipitated by the highly oxygenated nature of pulmonary tissue. As ROS generation is a byproduct of this metabolism, reducing power in the form of nicotinamide adenine dinucleotide phosphate (NADPH) is required to mitigate oxidative stress in response to this heightened mitochondrial activity. Nicotinamide nucleotide transhydrogenase (NNT) is known to sustain mitochondrial antioxidant capacity through the generation of NADPH; however, its function in non-small cell lung cancer (NSCLC) has not been established. We found that NNT expression significantly enhances tumor formation and aggressiveness in mouse models of lung tumor initiation and progression. We further show that NNT loss elicits mitochondrial dysfunction independent of substantial increases in oxidative stress, but rather marked by the diminished activities of proteins dependent on resident iron-sulfur clusters. These defects were associated with both NADPH availability and ROS accumulation, suggesting that NNT serves a specific role in mitigating the oxidation of these critical protein cofactors.